Related Experiment Video
Updated: Jun 2, 2026
05:51
Characterization of a Novel Human Organotypic Retinal Culture Technique
Published on: June 9, 2021
Anti-inflammatory therapy for diabetic retinopathy
Wenbo Zhang1, Hua Liu, Modesto Rojas
1Vascular Biology Center, Georgia Health Sciences University, Augusta, GA 30912-2500, USA. wezhang@georgiahealth.edu
Immunotherapy
|May 11, 2011
Summary
Diabetic retinopathy (DR) is a leading cause of blindness, with growing patient numbers and limited treatments. This review explores inflammation
Area of Science:
- Ophthalmology
- Endocrinology
- Immunology
Background:
- Diabetic retinopathy (DR) is a major complication of diabetes, causing significant vision loss in working-age adults.
- Current treatments for DR, including glycemic and blood pressure control, are insufficient, leading to a rising incidence and limited therapeutic options.
- Existing therapies for DR have notable limitations and side effects, highlighting the urgent need for novel prevention and treatment strategies.
Purpose of the Study:
- To investigate the role of chronic inflammation in the development and progression of diabetic retinopathy.
- To review and summarize current research on anti-inflammatory strategies for managing diabetic retinopathy.
Main Methods:
- Literature review focusing on studies investigating inflammation in diabetic retinopathy.
- Analysis of research on the efficacy and limitations of anti-inflammatory approaches for DR.
Main Results:
- Diabetic retinopathy exhibits significant features of chronic, subclinical inflammation.
- Emerging research suggests potential benefits of targeting inflammatory pathways in DR treatment.
Conclusions:
- Inflammation plays a crucial role in diabetic retinopathy pathogenesis.
- Developing new anti-inflammatory strategies is essential for effective prevention and treatment of DR, addressing the limitations of current therapies.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...